JANX on Nasdaq

Janux Therapeutics, Inc.

American pharmaceutical preparations company, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Zenas BioPharma, Inc., Spectrum Pharmaceuticals or PROTHENA CORP PUBLIC LTD CO, or pick any stock.

  • TickerJANX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Diego, California1
  • Incorporated inDE2
  • Business address10955 Vista Sorrento Parkway, Suite 200, San Diego, Ca 921302
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

We are an innovative clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying our proprietary technologies to our Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. The goal of our TRACTr and TRACIr platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system to eradicate tumors while minimizing safety concerns. Our initial focus is on developing a novel class of TRACTr therapeutics designed to target clinically validated TCE drug targets, while overcoming…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-1576.7%Operating margin4
-1136.2%Net margin4
-5.6%Revenue growth, 20254
-11.9%Return on equity4
-$83.3MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$125.9M

Out of $10.0M in revenue.4 The company lost money this year.

Financial statements

Revenue5674$10.0M in 2025
0$5.0M$10.0M$15.0M2020: $0$020202021: $3.6M$3.6M20212022: $8.6M$8.6M2022+137%2023: $8.1M$8.1M2023−6%2024: $10.6M$10.6M2024+31%2025: $10.0M$10.0M2025−6%
Operating income5674-$157.7M in 2025+3156% since 2020
-$200.0M-$150.0M-$100.0M-$50.0M02020: -$4.8M-$4.8M20202021: -$32.9M-$32.9M2021+580%2022: -$67.1M-$67.1M2022+104%2023: -$73.0M-$73.0M2023+9%2024: -$98.8M-$98.8M2024+35%2025: -$157.7M-$157.7M2025+60%
Net income5674-$113.6M in 2025+1575% since 2020
-$150.0M-$100.0M-$50.0M02020: -$6.8M-$6.8M20202021: -$32.7M-$32.7M2021+382%2022: -$63.1M-$63.1M2022+93%2023: -$58.3M-$58.3M2023−8%2024: -$69.0M-$69.0M2024+18%2025: -$113.6M-$113.6M2025+65%

Every line of the income statement as filed: the last 3 fiscal years, latest first.4

Period ending2025-12-312024-12-312023-12-31
Collaboration revenue$10.0M$10.6M$8.1M
Research and development$125.9M$68.4M$54.9M
General and administrative$41.8M$41.0M$26.1M
Total operating expenses$167.7M$109.4M$81.1M
Loss from operations-$157.7M-$98.8M-$73.0M
Interest income$44.0M$29.9M$14.7M
Total other income$44.0M$29.9M$14.7M
Net loss-$113.6M-$69.0M-$58.3M
Unrealized gain on available-for-sale securities, net$2.2M$1.5M$2.2M
Comprehensive loss-$111.5M-$67.5M-$56.1M
Net loss per common share, basic-$1.83-$1.28-$1.32
Net loss per common share, diluted-$1.83-$1.28-$1.32
Weighted-average shares of common stock outstanding, basic62.0M shares53.8M shares44.0M shares
Weighted-average shares of common stock outstanding diluted62.0M shares53.8M shares44.0M shares

Compare Janux Therapeutics, Inc. with another company

Leadership

Who has led Janux Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Tighe Reardon2021–2024
2025
Board members and other officers (23)

Filings

379 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 44 major events, 137 insider forms, 54 large holders, 124 other. The latest 20:

  1. Aug 14, 2026SCHEDULE 13G/A EDGAR
  2. Aug 13, 2026SCHEDULE 13G/A EDGAR
  3. Aug 6, 202610-Q EDGAR
  4. Aug 6, 20268-K EDGAR
  5. Jul 31, 20264 EDGAR
  6. Jul 28, 2026SCHEDULE 13G/A EDGAR
  7. Jul 10, 20264 EDGAR
  8. Jun 23, 20268-K EDGAR
  9. Jun 12, 20264 EDGAR
  10. Jun 12, 20264 EDGAR
  11. Jun 12, 20264 EDGAR
  12. Jun 12, 20264 EDGAR
  13. Jun 12, 20264 EDGAR
  14. Jun 12, 20264 EDGAR
  15. Jun 12, 20264 EDGAR
  16. Jun 12, 20268-K EDGAR
  17. Jun 4, 20264 EDGAR
  18. Jun 2, 2026144 EDGAR
  19. May 15, 2026SCHEDULE 13G/A EDGAR
  20. May 13, 20264 EDGAR

The 379 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

52 open-market trades by officers, directors and large owners since October 2021: 8 buys and 44 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 2, 2026Doyle Janeen NoelChief Corp. & Bus. Dev. OfcrSale4,059$14.03$56.9KForm 4
May 11, 2026Dobek MariaVice President, AccountingSale2,038$14.17$28.9KForm 4
Jan 2, 2026McIver ZachariahChief Medical OfficerSale2,714$13.73$37.3KForm 4
Jan 2, 2026Dobek MariaVice President, AccountingSale1,462$13.73$20.1KForm 4
Jan 2, 2026DiRaimondo ThomasChief Scientific OfficerSale2,505$13.73$34.4KForm 4
Jan 2, 2026Winter Charles M.Chief Technical OfficerSale2,401$13.73$33.0KForm 4
Jan 2, 2026Meyer Andrew HollmanChief Business OfficerSale1,879$13.73$25.8KForm 4
Jan 2, 2026Campbell David AlanPresident and CEOSale8,072$13.73$110.8KForm 4
Dec 1, 2025Meyer Andrew HollmanChief Business OfficerSale3,333$32.98$109.9KForm 4
Nov 14, 2025Meyer Andrew HollmanChief Business OfficerSale3,333$30.00$100.0KForm 4
Oct 28, 2025Meyer Andrew HollmanChief Business OfficerSale16,665$30.06$500.9KForm 4
May 1, 2025Meyer Andrew HollmanChief Business OfficerSale3,333$32.03$106.7KForm 4
Apr 21, 2025Meyer Andrew HollmanChief Business OfficerSale3,334$30.00$100.0KForm 4
Mar 7, 2025RA Capital Healthcare Fund LPDirectorBuy110,206$31.02$3.4MForm 4
Mar 6, 2025RA Capital Healthcare Fund LPDirectorBuy372,093$30.78$11.5MForm 4
Mar 5, 2025RA Capital Healthcare Fund LPDirectorBuy341,742$30.64$10.5MForm 4
Mar 3, 2025Meyer Andrew HollmanChief Business OfficerSale3,334$32.14$107.2KForm 4
Feb 3, 2025Meyer Andrew HollmanChief Business OfficerSale3,334$42.29$141.0KForm 4
Jan 7, 2025Campbell David AlanPresident and CEOSale5,000$60.00$300.0KForm 4
Jan 2, 2025Meyer Andrew HollmanChief Business OfficerSale13,334$54.88$731.8KForm 4

All 52 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Ra Capital Management, L.P.11,189,693$171.9M1.5%No change
BlackRock, Inc.6,134,667$94.2M0.0%+701,434
Prosight Management, LP3,804,481$58.4M10.1%+254,481
State Street Corp3,004,899$46.2M0.0%+540,882
Fmr LLC2,412,825$37.1M0.0%−122,899
Federated Hermes, Inc.2,352,927$36.1M0.1%+2,298,727
Point72 Asset Management, L.P.1,993,837$30.6M0.0%+837,697
Vanguard Capital Management LLC1,857,351$28.5M0.0%+45,986
TCG Crossover Management, LLC1,789,617$27.5M0.7%No change
Alyeska Investment Group, L.P.1,647,140$25.3M0.1%+46,051
Nantahala Capital Management, LLC1,619,828$24.9M0.8%+809,914
Wellington Management Group Llp1,507,360$23.2M0.0%−90,290
Vanguard Portfolio Management LLC1,330,710$20.4M0.0%+40,454
Two Sigma Investments, LP1,207,250$18.5M0.0%+1,091,151
Geode Capital Management, LLC1,204,150$18.5M0.0%+57,426
Citadel Advisors LLC1,200,737$18.4M0.0%+848,560
Algert Global LLC1,110,889$17.1M0.2%+667,492
D. E. Shaw & Co., Inc.1,096,509$16.8M0.0%+998,114
Goldman Sachs Group Inc952,675$14.6M0.0%+350,662
Bank Of America Corp /de/910,460$14.0M0.0%+108,814
Morgan Stanley836,966$12.9M0.0%+133,026
Qube Research & Technologies Ltd702,057$10.8M0.0%+504,912
Squarepoint Ops LLC532,321$8.2M0.0%−71,679
Orbimed Advisors LLC524,700$8.1M0.2%−458,900
Millennium Management LLC504,544$7.7M0.0%+117,734

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49